Data from the International Diabetes Federation show that 347 million people worldwide have diabetes, and the incidence is still rising. Although the treatment of diabetes has been advanced, the current therapeutic options and outcomes, e.g. complications, are yet far from ideal. Therefore, an urgent need exists for the development of more effective therapies. Numerous studies have been conducted to establish and confirm whether FGF21 exerts beneficial effects on obesity and diabetes along with its complications. However, most of the studies associated with FGF21 were conducted in the patients with type 2 diabetes. Subsequently, the effect of FGF21 in the prevention or treatment of type 1 diabetes and its complications were also increasingly reported. In this review, we summarize the findings available on the function of FGF21 and the status of FGF21's treatment for type 1 diabetes. Based on the available information, we found that FGF21 exerts a hypoglycemic effect, restores the function of brown fat, and inhibits various complications in type 1 diabetes patients. Although these features are predominantly similar to those observed in the studies that showed the beneficial impact of FGF21 on type 2 diabetes and its complications, there are also certain distinct features and findings that may be of provide important and instructive for us to understand mechanistic insights and further promote the prevention and treatment of type 1 diabetes.
[1]Jilin Univ, Hosp 1, Ctr Cardiovasc Disorders, Changchun, Jilin, Peoples R China.
[2]Univ Louisville, Dept Pediat, Pediat Res Inst, Louisville, KY 40292 USA.
[3]Wenzhou Med Univ, Affiliated Hosp 3, Ruian Ctr, Chinese Amer Res Inst Diabet Complicat, Ruian, Peoples R China.
[4]Univ Louisville, Dept Pharmacol & Toxicol, Louisville, KY 40292 USA.
(8.0+极速模式)